García-Rodríguez José Francisco, Bardán-García Belén, Juiz-González Pedro Miguel, Vilariño-Maneiro Laura, Álvarez-Díaz Hortensia, Mariño-Callejo Ana
Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, Sergas, 15405 Ferrol, Spain.
Department of Pharmacy, University Hospital of Ferrol, Sergas, 15405 Ferrol, Spain.
Antibiotics (Basel). 2020 Dec 26;10(1):15. doi: 10.3390/antibiotics10010015.
To evaluate clinical and antibiotic resistance impact of carbapenems stewardship programs.
descriptive study, pre-post-intervention, between January 2012 and December 2019; 350-bed teaching hospital. Prospective audit and feedback to prescribers was carried out between January 2015 and December 2019. We evaluate adequacy of carbapenems prescription to local guidelines and compare results between cases with accepted or rejected intervention. Analysis of antibiotic-consumption and hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs) was performed.
1432 patients were followed. Adequacy of carbapenems prescription improved from 49.7% in 2015 to 80.9% in 2019 ( < 0.001). Interventions on prescription were performed in 448 (31.3%) patients without carbapenem-justified treatment, in 371 intervention was accepted, in 77 it was not. Intervention acceptance was associated with shorter duration of all antibiotic treatment and inpatient days ( < 0.05), without differences in outcome. During the period 2015-2019, compared with 2012-2014, decreased meropenem consumption (Rate Ratio 0.58; 95%CI: 0.55-0.63), candidemia and hospital-acquired MDR BSIs rate (RR 0.62; 95%CI: 0.41-0.92, = 0.02), and increased cefepime (RR 2; 95%CI: 1.77-2.26) and piperacillin-tazobactam consumption (RR 1.17; 95%CI: 1.11-1.24), < 0.001.
the decrease and better use of carbapenems achieved could have clinical and ecological impact over five years, reduce inpatient days, hospital-acquired MDR BSIs, and candidemia, despite the increase in other antibiotic-consumption.
评估碳青霉烯类抗菌药物管理计划对临床及抗生素耐药性的影响。
采用描述性研究,于2012年1月至2019年12月期间进行干预前后对照研究;研究对象为一家拥有350张床位的教学医院。2015年1月至2019年12月期间对处方医生进行前瞻性审核并给予反馈。我们评估碳青霉烯类抗菌药物处方是否符合当地指南,并比较接受或拒绝干预的病例之间的结果。进行了抗生素消耗分析以及医院获得性多重耐药(MDR)血流感染(BSIs)分析。
共随访1432例患者。碳青霉烯类抗菌药物处方的合理性从2015年的49.7%提高到2019年的80.9%(P<0.001)。对448例(31.3%)无碳青霉烯类抗菌药物合理使用依据的患者进行了处方干预,其中371例接受了干预,77例未接受。干预的接受与所有抗生素治疗的持续时间缩短及住院天数缩短相关(P<0.05),但结局无差异。在2015 - 2019年期间,与2012 - 2014年相比,美罗培南消耗量下降(率比0.58;95%置信区间:0.55 - 0.63),念珠菌血症和医院获得性MDR BSIs发生率下降(RR 0.62;95%置信区间:0.41 - 0.92,P = 0.02),头孢吡肟消耗量增加(RR 2;95%置信区间:1.77 - 2.26)以及哌拉西林 - 他唑巴坦消耗量增加(RR 1.17;95%置信区间:1.11 - 1.24),P<0.001。
尽管其他抗生素消耗量有所增加,但在五年内实现的碳青霉烯类抗菌药物的减少及更合理使用可能对临床和生态产生影响,可减少住院天数、医院获得性MDR BSIs及念珠菌血症。